Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257577 | 0.94 | LTA4H (0.55) | LTA4HCA1CA2ENPP2MEN1 | |
| SCHEMBL3036082 | 0.93 | CYP2D6 (0.58) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL2555796 | 0.89 | RARB (0.58) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL3039053 | 0.88 | RARB (0.60) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL1792038 | 0.88 | RARB (0.60) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL7698504 | 0.88 | RARB (0.60) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL5392482 | 0.88 | RARB (0.60) | LTA4HCYP3A4CYP2D6CA1CA2 | |
| SCHEMBL623764 | 0.86 | CA1 (0.57) | LTA4HCA1CA2ENPP2LPL | |
| SCHEMBL3710609 | 0.85 | NQO1 (0.56) | LTA4HCA1CA2ENPP2ERN1 | |
| SCHEMBL17108413 | 0.84 | CYP3A4 (0.63) | LTA4HCYP3A4CYP2D6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180170904-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LTA4H 1649/4885CYP3A4 3867/4885CYP2D6 2993/4885 |
| US-20180170904-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | LTA4H 2332/4885CYP3A4 582/4885CYP2D6 1056/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LTA4H 1649/4885CYP3A4 3867/4885CYP2D6 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.